|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT01625871 |
|
Date of registration:
|
17/06/2012 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Artemether/Lumefantrine and Vivax Malaria
|
|
Scientific title:
|
Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan |
|
Date of first enrolment:
|
September 2011 |
|
Target sample size:
|
38 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT01625871 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
Phase:
|
Phase 3
|
|
|
Countries of recruitment
|
|
Sudan
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients with vivax malaria
Exclusion Criteria:
- severe malaria
- pregnancy
Age minimum:
5 Years
Age maximum:
80 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Vivax Malaria
|
|
Intervention(s)
|
|
Drug: tablets artemether/lumefantrine
|
|
Primary Outcome(s)
|
|
The cure rate
[Time Frame: 28 days]
|
|
Secondary Outcome(s)
|
|
Fever clearance time
[Time Frame: 28 days]
|
|
Parasite clearance time
[Time Frame: 28 days]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|